We have assessed levofloxacin penetration in cerebrospinal fluid (CSF) and the liquor-to-plasma ratio (C L /C P ) at 2 hours after dosing in 5 patients with spontaneous acute bacterial meningitis. CSF levofloxacin concentration at 2 hours after dosing was mg/mL, and the C L /C P at 2 hours after 1.99 ‫ע‬ 0.67 dosing was . 0.34 ‫ע‬ 0.09
isms [6] [7] [8] [9] . Moreover, an extensive passage through an altered blood brain barrier should be expected in humans, which is consistent with data that showed a levofloxacin liquor-toplasma ratio (C L /C P ) of 0.39 and 0.61 at 1 h and 7 h, respectively, after receipt of a loading dose followed by continuous iv infusion in rabbits that had an experimental meningitis [10] .
On these bases, levofloxacin (500 mg iv b.i.d., in 4 patients, and 500 mg q.d., in 1 patient with severe hepatic cirrhosis) was empirically added to a standard b-lactam regimen (iv cefotaxime, 2-3 g given every 6 hours, with or without iv ampicillin, 3 g given every 6 hours, or iv penicillin G, 4 million IU given every 4 hours) to provide a potential synergistic bactericidal activity during treatment of 5 patients with bacterial meningitis (mean age ‫ע‬ SD, years; sex, 3 male and 2 female 54 ‫ע‬ 25 patients; mean weight ‫ע‬ SD, kg). 74.40 ‫ע‬ 13.76 The aim of this study was to assess levofloxacin penetration into CSF and the C L /C P at 2 hours after dosing. This sampling time was chosen in light of the fact that the peak concentration of fluoroquinolones in CSF is expected to occur relatively rapidly after dosing, according to the fluoroquinolones' lipophilicity [11] , and because the mean time (‫ע‬SD) to achieve peak ofloxacin level in human CSF was found to be h 1.75 ‫ע‬ 1.25 [12] . CSF and blood samples were obtained after у48 h of levofloxacin therapy from all of the patients-that is, after the fluoroquinolones had achieved a steady state (range of duration of levofloxacin therapy before sampling, 2-13 days). Two mL of CSF were obtained during a diagnostic lumbar puncture performed 2 h after morning administration of levofloxacin (a 30-min iv infusion). Blood samples (4 mL) were obtained before and 0.5 h and 2 h after dosing during the same day; they were then centrifuged to obtain plasma. CSF and plasma samples were stored frozen at -20ЊC until assayed.
Levofloxacin plasma and CSF concentrations were analyzed by means of an HPLC method validated in our laboratory, which was based on the methods of Wong et al. [13] and Mack [14] , with some modifications. The analytical method that we chose was not stereospecific, because levofloxacin was shown to be stereochemically stable in body fluids without any metabolic inversion to D-ofloxacin [15] . In brief, 50 mL of internal standard stock solution (tinidazole, 60 mg/mL), 250 mL of phosphate buffer, and 5 mL of dichloromethane were added to 250 mL of a plasma or liquor sample, for extraction. After centrifugation, the organic portion was separated, evaporated under nitrogen, and then reconstituted with 150 mL of mobile phase. An aliquot of 50 mL was injected into the liquid chromatograph equipped with an ultraviolet detector ( nm) and eluted l p 280 with a mixed solution (82% KH 2 PO 4 plus 18% acetonitrile at pH 2.6) on a 5-mm C 18 precolumn that was linked to a 5-mm C 18 column at room temperature. Precision and accuracy were assessed by performing replicate analyses of quality control samples (0.2 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, 5 mg/mL, and 10 mg/mL) against calibration standards, with intra-and interassay coefficients of variation always being !10%. The low limit of detection was 0.1 mg/mL.
The etiologic agents were isolated in 4 of 5 cases (S. pneumoniae in 2 cases, E. coli in 1 case, and N. meningitidis in 1 case) and were shown to be sensitive to levofloxacin in vitro. Mean levels of levofloxacin in plasma (‫ע‬SD) before dosing and at 0.5 h and 2 h after dosing were mg/mL, 1.34 ‫ע‬ 0.80 mg/mL, and mg/mL, respectively, 8.16 ‫ע‬ 2.02 5.93 ‫ע‬ 1.11 whereas the mean CSF concentration (‫ע‬SD) at time 2 h after dosing was mg/mL. The mean levofloxacin C L /C P 1.99 ‫ע‬ 0.67 (‫ע‬SD) at 2 h after dosing was (range, 0.23-0.42). 0.34 ‫ע‬ 0.09 Although CSF analyses seem to suggest that higher penetration occurred in those patients who showed a greater extent of meninges inflammation (table 1), the penetration of fluoroquinolones into CSF is often considered to be minimally affected by the presence of inflammation, because of lipophilicity [11] . At 30-day follow-ups, all patients showed total recovery with no sequelae.
Although they referred to only a single sampling time (2 h after dosing), to our knowledge, these preliminary data represent the first to have documented levofloxacin concentration in CSF in patients with bacterial meningitis. Our results are partially in agreement with the findings of other authors regarding levofloxacin and ofloxacin penetration into CSF. Ohi et al. [17] showed that CSF levels of levofloxacin 3 h after a single 200-mg dose ranged from 0.16 mg/mL to 0.51 mg/mL, with a C L /C P ratio that ranged from 0.08 to 0.24. The greater ratio found in our patients may be explained once we consider that, although the aforementioned data referred to a singledose study in volunteers with uninflamed meninges, our findings referred to a multiple-dose study with a different CSF sampling time (2 h vs. 3 h) after that steady state was achieved in meningitis patients. As far as racemic ofloxacin penetration into CSF is concerned, Nau et al. [12] showed that an average ofloxacin CSF peak of ∼2 mg/mL was achieved 0.5-4 h after a single 30-min iv infusion of a 400-mg dose of ofloxacin in 6 patients who had cerebrovascular diseases with uninflamed meninges.
If we consider that, from a pharmacodynamic standpoint, a peak MIC ratio of у10 was shown to be one of the major determinants for the concentration-dependent bactericidal activity of fluoroquinolones, and that optimal antibiotic therapy of meningitis requires bactericidal activity within the CSF with concentrations that are at least 8-10-fold higher than the mean bactericidal concentration for the infecting organism [5] , these preliminary CSF pharmacokinetic data suggest that a 500-mg dose of levofloxacin given b.i.d. could be helpful in the management of bacterial meningitis, whose causative pathogens have an MIC of р0.1-0.2 mg/mL. Such circumstances are feasible in infections with H. influenzae, N. meningitidis, E. coli, and other Enterobacteriaceae.
